Advertisement

Drugs & Therapy Perspectives

, Volume 29, Issue 11, pp 329–335 | Cite as

DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Hexacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe

  • Katherine A. Lyseng-WilliamsonEmail author
  • Paul L. McCormack
Adis Drug Clinical Q&A

Abstract

Hexyon®/Hexacima® (DTaP-IPV-Hep B-Hib) is a new thiomersal-free hexavalent combination paediatric vaccine indicated for the primary and booster vaccination of infants and toddlers from 6 weeks to 24 months of age in Europe. Clinical data indicate that vaccination with this vaccine is a safe and immunogenic option for providing protection against the serious childhood infections of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b. Its fully liquid ready-to-use formulation is convenient and simplifies administration by healthcare professionals.

Keywords

Pertussis Diphtheria Booster Vaccination Primary Vaccination Varicella Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

The manuscript was reviewed by: G. Gabutti, Department of Prevention, O.U. Hygiene and Public Health, LHU4 “Chiavarese” - Regione Liguria, Chiavari, Italy; M.E. Pichichero, Centre for Infectious Diseases and Immunology, Rochester General Hospital, Rochester, NY, USA.

Disclosure

This article was adapted from Pediatric Drugs 2013;15(1):59–70 [19]. The preparation of these reviews was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

References

  1. 1.
    World Health Organization. WHO recommendations for routine immunization: summary tables. 2012. http://www.who.int/immunization/policy/immunization_tables/en/. Accessed 12 July 2013.
  2. 2.
    Skibinski DAG, Baudner BC, Singh M, et al. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Hexyon suspension for injection: summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
  4. 4.
    Hexacima suspension for injection: summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
  5. 5.
    Plotkin SA, Liese J, Madhi SA, et al. A DTaP-IPV//PRP-T vaccine (Pentaxim™): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011;10(7):981–1005.PubMedCrossRefGoogle Scholar
  6. 6.
    Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years. Vaccine. 2010;28(20):3595–601.PubMedCrossRefGoogle Scholar
  7. 7.
    Madhi SA, Mitha I, Cutland C, et al. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J. 2011;30(4):e68–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15–18 months compared to licensed vaccines in Turkish infants [abstract plus poster]. 5th Asian Congress of Pediatric Infectious Diseases; 23–26 Sep 2010; Taipei.Google Scholar
  9. 9.
    Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96.PubMedGoogle Scholar
  10. 10.
    Becerra Aquino AG, Gutierrez Brito M, Aranza Doniz CE, et al. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine. 2012;30(45):6492–500.CrossRefGoogle Scholar
  11. 11.
    Lanata C, Zambrano B, Ecker L, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in Peru. J Vaccines Vaccin. 2012;3(1):1000128.CrossRefGoogle Scholar
  12. 12.
    Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56.PubMedCrossRefGoogle Scholar
  13. 13.
    Lopez P, Arguedas A, Consuelo-Miranda M, et al. Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America [abstract no. A3L24]. 15th International Congress on Infectious Diseases; 13–16 June 2012; Bangkok.Google Scholar
  14. 14.
    Madhi SA, Koen A, Cutland C, et al. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15–18 months of age in healthy South African infants. Pediatr Infect Dis. 2013;32(8):889–97.Google Scholar
  15. 15.
    Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):e24–30.PubMedCrossRefGoogle Scholar
  16. 16.
    World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84(40):405–19.Google Scholar
  17. 17.
    Macias M, Lanata CF, Zambrano B, et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatr Infect Dis J. 2012;31(8):e126–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Santos-Lima E, B’Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) following primary series administration at 2, 4, 6 months of age in Latin America. Vaccine. 2013;31(9):1255–8.PubMedCrossRefGoogle Scholar
  19. 19.
    McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Pediatr Drugs. 2013;15(1):59–70.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Katherine A. Lyseng-Williamson
    • 1
    Email author
  • Paul L. McCormack
    • 1
  1. 1.AdisAucklandNew Zealand

Personalised recommendations